📌 Key Takeaways
- Topic: CMP Slurry Silica: Colloidal vs Fumed Silica for Chemical Mechanical Polishing
- Keywords: microsilica
- Published: 2026-11-20 00:33:07
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Silicon Dioxide CAS 7631-86-9: Identification, Properties and Regulatory Information
- What Is Cristobalite? Properties, Uses and How It Differs from Quartz
- Peng, C., Huang, Y. & Zheng, J. Renal clearable nanocarriers: Overcoming the physiological hurdles for precise drug delivery and clearance. J. Control. Release 322, 64-80 (2020). Article CAS PubMed Central PubMed Google Scholar
- Silica Powder Supplier Guide: How to Compare Grades, Quality and Pricing
- Quartz Sand Supplier: How to Choose by Purity, Grain Size and Logistics
- Huo, M., Wang, L., Chen, Y. & Shi, J. Tumor-selective catalytic nanomedicine by nanocatalyst delivery. Nat. Commun. 8, 357 (2017). Article PubMed Central PubMed Google Scholar
- Silicon Dioxide Chemical Properties: Reactivity, Stability and Key Reactions
What Is a Low CTE Filler? Why Fused and Spherical Silica Are Preferred
What is silica (SiO₂)?
is silicon dioxide safe Su, G. et al. Mesoporous silica doped with different water-soluble ligands to enhance the antibacterial performance of nano zinc oxides by coordination effect. Coll. Surf. A Physicochem. Eng. Asp. 640, 128414 (2022). Piece CAS Google Scholar
What is the difference between fumed silica and precipitated silica?
silica distributor Liu, X. & Che, S. Boosted release of the poorly soluble drug itraconazole loaded in ordered mesoporous silica. Sci. China Chem. 58, 400-410 (2015). Article CAS Google Scholar
What drives silica raw material prices?
silica for floor coatings Secondly, it is needed to construct simple but efficient MSNs-based nanoplatforms. The abundant traits of MSNs have led to their vast exploitation as multifunctional nanocarriers, and this may be accompanied by the introduction of two or more elements into MSNs. Although these multifunctional nanoplatforms have proven to be really effective in numerous papers, the complexity of these platforms does not appear to be friendly to the scale-up preparation and clinical translation. On the one hand, it is well known that the laboratory-level synthesis methods of MSN are very different from those used for industrial scale-up production required for clinical screening and use. The reproducibility and batch stability of nanoformulations are always an important component to consider in industrial scale-up production, and in this process, simplifying the production steps is the key to promote the industrial scale-up production. Nonetheless, the complex MSNs-based nanoplatforms call for higher nanoformulation preparation technologies and more stringent storage methods, which often call for more time, effort, and economic investments. On the other hand, the multiple components may introduce more unsafe factors, it appears to be an enormous challenge at this stage to systematically reveal the toxicity mechanisms of these different components when we still do not entirely understand the toxicity mechanisms of MSNs. Hence, it is advocated to slim down the MSNs-based platform as much as possible while meeting the clinical requirements.
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.